Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sana Biotechnology, Inc. before investing.

In this article, we go over a few key elements for understanding Sana Biotechnology, Inc.’s stock price such as:

• Sana Biotechnology, Inc.’s current stock price and volume
• Why Sana Biotechnology, Inc.’s stock price changed recently
• Upgrades and downgrades for SANA from analysts
• SANA’s stock price momentum as measured by its relative strength

About Sana Biotechnology, Inc. (SANA)

Before we jump into Sana Biotechnology, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Want to learn more about Sana Biotechnology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Sana Biotechnology, Inc..

Sana Biotechnology, Inc.’s Stock Price as of Market Close

As of May 08, 2026, 10:33 AM, CST, Sana Biotechnology, Inc.’s stock price was $3.515.

Sana Biotechnology, Inc. is up 0.43% from its previous closing price of $3.500.

During the last market session, Sana Biotechnology, Inc.’s stock traded between $3.440 and $3.580. Currently, there are approximately 275.88 million shares outstanding for Sana Biotechnology, Inc..

Sana Biotechnology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Sana Biotechnology, Inc. Stock Price History

Sana Biotechnology, Inc.’s (SANA) price is currently up 6.84% so far this month.

During the month of May, Sana Biotechnology, Inc.’s stock price has reached a high of $3.710 and a low of $3.180.

Over the last year, Sana Biotechnology, Inc. has hit prices as high as $6.550 and as low as $1.600. Year to date, Sana Biotechnology, Inc.’s stock is down 13.64%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Sana Biotechnology, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there was 1 analyst who downgraded Sana Biotechnology, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Sana Biotechnology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Sana Biotechnology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Sana Biotechnology, Inc. (SANA) by visiting AAII Stock Evaluator.

Relative Price Strength of Sana Biotechnology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Sana Biotechnology, Inc. has a weighted four-quarter relative price strength of 9.17%, which translates to a Momentum Score of 79 and is considered to be Strong.

Want to learn more about how Sana Biotechnology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Sana Biotechnology, Inc. Stock Price: Bottom Line

As of May 8, 2026, Sana Biotechnology, Inc.’s stock price is $3.515, which is up 0.43% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Sana Biotechnology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.